Company intelligence / Profile preview

KTB Tumorforschungsgesellschaft

Freiburg, Baden-Württemberg, Germany

Ownership: Private
Development stage: Other

Overview

KTB Tumorforschungsgesellschaft developed technology platforms and drug discovery services focused on cancer protein kinase targets, offered translational capabilities for biomarker and inhibitor development, and was active in collaborative grant-funded research with several R&D programs, but entered insolvency proceedings and was acquired after 2015[1][3][5].

Therapeutic areas: OncologyNeurology
Modalities: Small moleculeProtein kinase inhibitor
Industry: Biotech

Drug pipeline

1 asset

AW054

Preclinical

Partnerships

Proteome Sciences R&D GmbH & Co. KGNMI Natural and Medical Sciences Institute at University of TübingenAntibodies by Design (MorphoSys AG division)

Beyond the preview

Go deeper on KTB Tumorforschungsgesellschaft.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on KTB Tumorforschungsgesellschaft.

Explore the full profile